Modern chronic disease care rests on a paradox so blatant we have become desensitized to it. We possess pharmacotherapies that halt disease progression, monitoring technologies that predict decompensation, and decades of trial data defining gold-standard pathways. Yet the organizational structures that mediate access to these tools—specifically, the design of commercial and government-sponsored insurance—are engineered with friction points that systematically thwart sustained engagement. This is not incompetence. It is a quiet, actuarial logic that prioritizes short-term cost containment over long-term morbidity reduction, and it demands a rigorous, unsentimental autopsy.
When I encounter the standard narrative that patients with type 2 diabetes, heart failure, or COPD simply fail to adhere, I see a profound analytical failure. The unit of analysis is wrong. We blame the individual while ignoring the structural sieve through which that individual must continuously pass. Let us examine the sieve.
Prior Authorization as a Non-Adherence Machine
Prior authorization (PA) is presented as a guardrail against unnecessary utilization. In chronic disease, it functions as an interruption of care. Consider a patient with rheumatoid arthritis stabilized on a biologic. Mid-year, the insurer alters its formulary, requiring a new PA or step therapy through a less effective conventional synthetic DMARD. The process demands a phone call, a fax, a peer-to-peer review, and a waiting period that can stretch from three days to three weeks. During this interval, the patient is not on treatment. Disease activity re-emerges. The cumulative damage to synovial tissue is irreversible.
The administrative overhead is not a trivial side effect; it is the primary mechanism. A 2023 survey by the American Medical Association found that 94% of physicians reported care delays associated with PA, and 33% reported that PA had led to a serious adverse event for a patient in their care. The insurer’s response—that these are exceptions—misses the point. The design tolerates these exceptions because the system’s goal is not zero harm but aggregate cost shifting. Every denied or delayed dose of a disease-modifying agent reduces pharmacy spend in the current quarter. The resulting hospitalization for a flare or myocardial infarction falls into a different fiscal year, a different budget, perhaps a different insurer entirely. The architecture is rational if your horizon is 12 months. It is destructive if your horizon is a human life.
Cost-Sharing Structures That Penalize Disease Control
High-deductible health plans (HDHPs) are predicated on a behavioral economic assumption: that consumers will shop for value, reducing unnecessary care. Chronic disease explodes this premise. A patient with insulin-dependent diabetes does not have the option to forgo insulin, continuous glucose monitoring sensors, or quarterly endocrinology visits. These are not discretionary purchases. Yet under an HDHP, the patient faces the full negotiated price of these necessities until the deductible is satisfied, often several thousand dollars.
The empirical data on the consequences are unambiguous. A widely cited study in JAMA Internal Medicine demonstrated that when low-income adults with diabetes were switched to HDHPs, they experienced statistically significant delays in seeking care for acute complications, including hyperglycemia and cellulitis. The mechanism is rational: faced with a $400 sensor transmitter and a $150 endocrinologist copay in January, a patient on a fixed income engages in what economists euphemistically call “consumption smoothing.” The clinical term is dose rationing or appointment skipping. The long-term cost of a single skipped appointment can be a below-knee amputation. That cost will eventually land on Medicare, not the commercial plan that designed the deductible.
Specialty tier coinsurance—where a patient pays 20% to 30% of a drug’s list price rather than a flat copay—is a more precise instrument of exclusion. For a PCSK9 inhibitor prescribed after a second myocardial infarction, the patient’s monthly share can exceed $300. The clinical trial evidence for these agents is solid; they reduce LDL cholesterol and cardiovascular events. The insurer’s rebuttal is that the patient can try a high-intensity statin first. But when the statin is maximized and the LDL remains above threshold, the coinsurance barrier represents not a clinical judgment but a financial gate. The patient does not fill the prescription. The insurer reports a low uptake rate as evidence of low demand, a circular logic that justifies maintaining the barrier.
Narrow Networks and the Disruption of Therapeutic Relationships
Network design is the most underappreciated tool of access restriction. A patient with lupus builds a clinical relationship with a rheumatologist over years. The rheumatologist understands the subtle shifts in disease activity, the patient’s tolerance for specific immunomodulators, the interplay between organ systems. When an employer switches insurance carriers to reduce premiums, the patient discovers that the rheumatologist is now out-of-network. The cost to continue care becomes prohibitive, or the insurer simply refuses to cover any out-of-network visits.
The patient is forced to establish care with a new, in-network rheumatologist. Records must be transferred. The new physician must reconstruct a complex history from documentation that is often incomplete. Appointments are scheduled six months out. In the interim, the patient’s disease is unmonitored. This is a form of iatrogenic instability generated entirely by the business of insurance. The clinical literature on continuity of care is consistent: a disrupted therapeutic relationship predicts worse outcomes, lower medication adherence, and higher emergency department utilization. The insurer’s network design treats physicians as interchangeable service units, a fallacy that any clinician who has managed a complex chronic condition recognizes as dangerous.
The Formulary Treadmill and Therapeutic Switching
Non-medical switching is the practice of changing a stable patient’s medication to a therapeutically similar but not identical agent for purely financial reasons. An insurer negotiates a rebate agreement with a manufacturer of a specific SGLT2 inhibitor. Mid-year, the formulary changes. The patient with heart failure, stable on empagliflozin for two years, receives a letter stating that dapagliflozin is now the preferred product. The clinical nuance—differences in receptor selectivity, patient tolerance, minor but real variations in outcome data—is dismissed. The switch is mandated.
The patient may experience side effects from the new agent. A rebound in blood pressure, a change in glycemic control, a bout of fatigue. The physician must now manage an adverse event created not by disease progression but by formulary engineering. The insurer saves 15% on net drug cost after rebate. The downstream cost of the extra office visit, the additional monitoring, the potential emergency department visit—these are externalized. The patient’s trust in the therapeutic plan erodes. The physician’s authority is undermined. Chronic disease management requires stability and predictability; the formulary treadmill injects chaos.
Coding Constraints and the Invisibility of Complexity
Reimbursement codes are reductionist by necessity, but their structure actively discourages the management of multimorbidity. A primary care physician is paid for a 15-minute visit coded for diabetes. In that 15 minutes, the patient also has hypertension, depression, and early-stage CKD. The physician must address all of these, but the payment does not scale with complexity beyond a modest modifier. The result is that chronic disease care is compressed into impossible time windows. Discussions about diet, exercise, medication adherence, side effects, and social barriers are rushed or omitted.
Value-based payment models claim to address this, but many are structured around single-disease metrics—HbA1c control, for example. A physician who improves a patient’s HbA1c but simultaneously manages that patient’s depression and food insecurity receives no additional compensation for the latter activities. The incentive is to focus narrowly on the metric that triggers the bonus, not on the patient as a whole. This is not a failure of individual physicians; it is a rational response to a payment architecture that renders whole-person chronic disease management economically unsupportable in primary care.
Step Therapy and the Logic of Delayed Efficacy
Step therapy mandates that a patient fail on one or more lower-cost medications before the insurer will cover a more expensive agent. For acute conditions, this can be a defensible approach. For chronic, progressive diseases, it is often a clinical gamble with high stakes. A patient with psoriatic arthritis must first fail methotrexate before accessing a biologic, even if clinical presentation suggests a high likelihood of rapid joint destruction. The “failure” is not just a prescription that does not work; it is months of active inflammation, pain, and functional decline.
The insurer’s protocol does not account for the cumulative, irreversible damage that occurs during the step period. Joint erosion, work disability, opioid dependence for pain management—these are not captured in the pharmacy benefit manager’s spreadsheet. The step therapy algorithm is built on population-level cost-effectiveness models that smooth over the individual tragedies. A patient who develops radiographic progression during the required methotrexate trial has suffered a permanent loss of function. The insurer has saved a few thousand dollars. The societal cost, in lost productivity and future surgical interventions, is an order of magnitude larger.
Fragmentation of Benefits and the Pharmacy-Medical Divide
The separation of pharmacy benefits from medical benefits creates a perverse incentive structure. A pharmacy benefit manager (PBM) is charged with controlling drug spending. A health plan covers hospitalizations and procedures. An expensive biologic that prevents hospitalizations for Crohn’s disease looks like a cost to the PBM but a saving to the medical plan. When these two entities are under separate financial umbrellas, the PBM has zero incentive to cover the drug generously. It imposes prior authorization, step therapy, high coinsurance, or outright exclusions.
The patient with Crohn’s disease, unable to afford the biologic, experiences a flare. The flare leads to a bowel obstruction, a hospitalization, and a surgical resection. The medical plan pays $60,000 for the inpatient stay and surgery. The PBM has saved $10,000 in drug costs. From a health system perspective, this is a $50,000 loss plus a permanently altered anatomy. From the PBM’s balance sheet, it is a success. This fragmentation is not an accident of history; it is a profitable arrangement for intermediaries who extract value from the lack of coordination. The patient’s body is the site where these misaligned incentives become tissue damage.
Toward a More Honest Architecture
We can’t just tinker around the edges of these policies. We do not need streamlined prior authorization; we need to eliminate it for evidence-based chronic disease therapies. We do not need lower deductibles; we need first-dollar coverage for disease-modifying agents, funded by a recognition that preventing a $50,000 hospitalization with a $10,000 drug is a net gain. We do not need narrower networks with better directories; we need network adequacy standards that protect established therapeutic relationships.
Any honest appraisal must acknowledge the political economy here. These barriers are not bugs; they are features for entities whose revenue models depend on short-term cost shifting. The employer who contracts with an insurer sees a slightly lower premium increase and does not see the amputation or the heart failure readmission three years later. The PBM that extracts a rebate from a manufacturer does not internalize the patient’s suffering. The system is perfectly tuned to obscure the causal chain linking insurance design to clinical outcomes. It requires a deliberate, disciplined effort to trace those chains and to insist that the unit of accountability is the design itself, not the patient who collapses under its weight.
Chronic disease is, by definition, a long game. It demands a care architecture that matches its temporal scale—one that values continuity, rewards prevention, and removes rather than multiplies the administrative burdens placed on patients and clinicians. The current architecture fails this test. It is time to name it for what it is: a mechanism of structural neglect, dressed in the language of actuarial prudence.
Frequently Asked Questions
Why do insurers use prior authorization if it causes delays?
Insurers deploy prior authorization primarily as a cost-containment tool. By requiring clinicians to justify a treatment before it is covered, the insurer creates friction that reduces utilization. Some requests are abandoned entirely. Others are delayed, pushing the cost into a future coverage period. The insurer frames this as evidence-based gatekeeping, but the evidence used is often population-level cost-effectiveness data that ignores individual patient history and disease severity.
How do high deductibles specifically affect diabetes management?
High deductibles force patients with diabetes to pay the full negotiated price for insulin, glucose monitoring supplies, and specialist visits until they meet their deductible. This can mean over $1,000 in out-of-pocket costs in January alone. Patients respond by rationing insulin, reusing needles, or skipping glucose checks. These behaviors lead to preventable episodes of ketoacidosis, severe hypoglycemia, and long-term vascular complications that are far more expensive to treat than the original preventive care.
What is non-medical switching and why is it dangerous?
Non-medical switching occurs when an insurer changes its formulary to favor a different brand or generic within the same therapeutic class, forcing stable patients to switch medications for financial rather than clinical reasons. It is dangerous because even drugs in the same class can have different side effect profiles, dosing schedules, and efficacy in specific patient subgroups. A patient who has been stable for years may experience a flare of disease activity or new adverse effects, all to capture a manufacturer rebate for the insurer.
Can value-based care fix these insurance design problems?
Value-based care models, in theory, align payment with outcomes rather than volume. In practice, many models still focus on single-disease metrics over short time horizons. They do not automatically eliminate prior authorization, narrow networks, or high cost-sharing. Unless a value-based contract specifically penalizes insurers for the downstream consequences of access barriers—and unless those contracts span multiple years—they may simply add another layer of administrative complexity without dismantling the structural barriers described here.
This analysis is not an argument for a specific policy solution but a demand for analytical clarity. The barriers to chronic disease management are not mysterious. They are designed. They can be redesigned.